The Middle East & Africa Urinary Tract Infection Market Can Bag a Valuation of $992.84 Mn by 2022: MRFR
Global Urinary Tract Infections Market: Information By Drug Class (Quinolones (Ciprofloxacin, Enoxacin, Norfloxacin, Ofloxacin, Pefloxacin, Fleroxacin), Β-Lactam & Cephalosporins (Amoxicillin-Clavulanate, Cefdinir, Cefaclor, Cefpodoxime-Proxetil), Aminoglycosides, Penicillin, Azoles), Application (Urethritis, Cystitis, Pyelonephritis), Pathogen (Escherichia coli, Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis), End-User (Hospitals, Clinics, Self-Administered) and Region (Americas, Europe, Asia-Pacific, Rest of the World) - Forecast till 2027
Overview:
The Middle East & Africa (MEA) urinary tract infection (UTI) market is gaining momentum as awareness regarding the disease is witnessing a gradual increase in awareness. Wealthy economies are sparsely located in different pockets of the region enabling a slower growth in the healthcare sector compared to its peers. The region does not invest much in research & development and other activities. Yet, the awareness regarding urinary tract infection is growing with the assistance of governments and various NGOs. The infection mainly happens due to the presence of Escherichia coli in the urinary tract. Pain with urination, frequent urination and feeling the need to urinate despite having an empty bladder are symptoms common with urinary tract infection. The MEA urinary tract infection market is expecting a rise by 4.35% CAGR during the forecast period (2017-2022) and a valuation of USD 992.84 million in that given period, asserts Market Research Future (MRFR). The report also identifies factors such as catheter-associated UTI, hospital-borne infections (nosocomial infections), childbirth, old age, obesity, and increasing health awareness among women as possible MEA urinary tract infection market influencers.
However, several factors can be counted as a hindrance for the MEA urinary tract infection market growth during the forecast period. Factors such as drug resistance, unmet clinical needs, increasing incidence of chronic diseases, etc. can weaken the expected CAGR during the forecast period.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/6138
Segmentation:
The MEA urinary tract infection market can be segmented by drug class, clinical indications, and end-users.
Based on the drug class, the MEA urinary tract infection market can be segmented into quinolones, aminoglycosides, β-lactam, azoles, and others.
On the basis of clinical indications, the MEA urinary tract infection market includes urethritis, cystitis, and pyelonephritis.
Based on the end-users, the MEA urinary tract infection market can be segmented into hospitals and self-administered.
Regional Analysis:
The MEA urinary tract infection market report, based on countries, includes namely United Arab Emirates (UAE), Egypt, Saudi Arabia, Kuwait, Qatar, and Oman.
The UAE has the largest market for urinary tract infection. The region has superior technology and healthcare infrastructure than the rest. Furthermore, it gets support from government initiatives that aim at spreading awareness. Egypt assumes the second lead with the considerable investment made in the sector. South Africa in the African continent is doing remarkably well due to the presence of several Indian pharmaceutical companies. However, other countries can only expect prolonged growth due to the lack of medical infrastructure and unmet needs for medicine.
Competitive Market:
Some of the key players in this MEA urinary tract infection market are Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Dr. Reddy’s Laboratories Ltd., and others.
Industry Updates:
In July 2018, Cipla Inc. announced their plan to increase their business in Africa by taking the route of merger and acquisition. The process they started by taking over Mirren, an over-the-counter medicine manufacturer. Cipla’s further proliferation would increase awareness and help in the growth of the market.
Procter and Gamble (P & G) has taken the initiative to reduce the number of girls suffering from urinary tract infection by investing heavily in educational campaigns in East African countries. The company has started distributing samples and starter packs to girls studying in a school in a bid to protect girls from contracting the infection.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/urinary-tract-infection-market-6138
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com
